Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

the role of metformin when combined with traditional metastatic breast cancer treatment in non-diabetic patients compared to diabetic patients who are not using metformin. In this randomized control study, there will be a demonstration either it is effective to suppress tumor burden or not through normal screening for tumor.

Inclusion criteria

• The non-diabetic patients will be included in the study if they meet the following criteria:

• Confirmed metastatic breast cancer (IV stage) radiologically or by clinical evaluation receiving chemotherapy
• Age between 18- 70 years.
• Life expectancy at least 6 months

Exclusion criteria

• The patients will be excluded from the study if they have the following criteria:

• Bad prognosis disease: Criteria defined as the following

• If patient >70 years
• If patient has bad site metastasis (brain)
• Hypersensitivity for metformin: if happened patient will be treated as following

• Pheniramine Maleate 3 times daily for 7 days and Tablet Dexamethasone 1mg daily in 2 divided doses for 5 days [16].
• Any condition associated with increased risk of metformin-associated lactic acidosis (e.g., congestive heart failure defined as New York Heart Association {NYHA} Class III or IV functional status; the history of acidosis of any type, severe infections, kidney or liver disease, respiratory disease, seizures .
• Diabetic patients.